• Price Momentum

    MRNA is trading near the bottom of its 52-week range and below its 200-day simple moving average.

  • Price change

    The price of MRNA shares has decreased $0.61 since the market last closed. This is a 2.28% drop.

  • Opened at $26.21.

    The stock opened $0.53 lower than its previous close.

Key terms

About MRNA

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
  • Market cap: $10.44B

    A market capitalization between $10 billion and $200 billion places MRNA in the large capitalization category.

Key terms

Smart score

Latest MRNA news

Today 7:33am ET VOO ETF News: Fast Daily Recap – 10/14/25 Yesterday 1:50pm ET SPY ETF News, 10/13/2025 Yesterday 9:40am ET Moderna presents ‘promising’ early data for cancer antigen therapy Yesterday 8:17am ET VOO ETF News: Fast Daily Recap – 10/13/25 Oct 10, 2025 1:14pm ET SPY ETF News, 10/10/2025 Oct 10, 2025 10:50am ET Mixed options sentiment in Moderna with shareslittle changed Oct 10, 2025 8:11am ET Moderna price target raised to $32 from $31 at Morgan Stanley Oct 10, 2025 8:11am ET VOO ETF News, 10/10/2025 Oct 09, 2025 9:50pm ET RBC Capital Sticks to Its Hold Rating for Moderna (MRNA) Oct 09, 2025 2:12pm ET SPY ETF News, 10/9/2025 Oct 08, 2025 2:40pm ET SPY ETF News, 10/8/2025 Oct 08, 2025 6:57am ET VOO ETF News, 10/8/2025 Oct 07, 2025 2:03pm ET SPY ETF News, 10/7/2025 Oct 07, 2025 7:35am ET VOO ETF News, 10/7/2025 Oct 06, 2025 12:15pm ET SPY ETF News, 10/6/2025 Oct 06, 2025 6:51am ET VOO ETF News, 10/6/2025 Oct 03, 2025 3:09pm ET SPY ETF News, 10/3/2025 Oct 03, 2025 10:50am ET Moderately bullish activity in Moderna with shares up 0.65% Oct 03, 2025 6:42am ET VOO ETF News, 10/3/2025 Oct 02, 2025 1:32pm ET SPY ETF News, 10/2/2025 Oct 02, 2025 11:24am ET VOO ETF News, 10/2/2025 Oct 01, 2025 3:04pm ET SPY ETF News, 10/1/2025 Oct 01, 2025 9:55am ET Early notable gainers among liquid option names on October 1st Oct 01, 2025 8:55am ET VOO ETF News, 10/1/2025 Oct 01, 2025 5:55am ET Bernstein Sticks to Its Hold Rating for Moderna (MRNA) Sep 30, 2025 1:27pm ET SPY ETF News, 9/30/2025 Sep 30, 2025 10:45am ET VOO ETF News, 9/30/2025 Sep 29, 2025 2:01pm ET SPY ETF News, 9/29/2025 Sep 29, 2025 10:15am ET VOO ETF News, 9/29/2025 Sep 26, 2025 4:45pm ET Mixed options sentiment in Moderna with shares down 0.43% Sep 26, 2025 1:37pm ET SPY ETF News, 9/26/2025
Oct 12, 2025 6:05pm ET Moderna Presents Promising Early Data for Its Investigational Cancer Antigen Therapy at the 2025 European Society for Medical Oncology Congress Sep 24, 2025 7:01pm ET Moderna Opens State-of-the-Art Manufacturing and R&D Facility in the UK Sep 23, 2025 7:00am ET Moderna Announces mNEXSPIKE Generates Strong Immune Response Against LP.8.1 Variant in Humans Sep 19, 2025 3:10pm ET Moderna Announces First Made-in-Canada mRNA Vaccines Delivered to Canadian Provinces and Territories Sep 16, 2025 6:00am ET Moderna Announces Updated COVID-19 Vaccine Against LP.8.1 Variant Generates Strong Immune Response in Humans Sep 02, 2025 7:00am ET Moderna Announces Data to be Presented at the 2025 International Congress of Inborn Errors of Metabolism Aug 27, 2025 1:24pm ET Moderna Receives U.S. FDA Approval for Updated COVID-19 Vaccines Targeting LP.8.1 Variant of SARS-CoV-2 Aug 22, 2025 9:25am ET Moderna Receives Health Canada Approval for Updated COVID-19 Vaccine Targeting SARS-CoV-2 Variant LP.8.1 Aug 21, 2025 7:00am ET Moderna to Present at Upcoming Conferences in September 2025 Aug 01, 2025 7:00am ET Moderna Reports Second Quarter 2025 Financial Results and Provides Business Updates Aug 01, 2025 6:00am ET UK Court of Appeal Confirms Moderna’s EP'949 Patent is Valid and Infringed by Pfizer/BioNTech Jul 30, 2025 4:05pm ET Moderna Receives European Commission Approval for Updated COVID-19 Vaccine Targeting SARS-CoV-2 Variant LP.8.1 Jul 28, 2025 7:00am ET Moderna Announces Data to be Presented at ESMO Congress 2025 Jul 25, 2025 8:45am ET EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's COVID-19 mRNA Vaccine Targeting the SARS-CoV-2 Variant LP.8.1 Jul 11, 2025 7:00am ET Moderna to Report Second Quarter 2025 Financial Results on Friday, August 1, 2025 Jul 10, 2025 8:00am ET Moderna Receives Full U.S. FDA Approval for COVID-19 Vaccine, Spikevax, in Children Aged 6 Months Through 11 Years at Increased Risk for COVID-19 Disease Jun 30, 2025 7:00am ET Moderna Announces Positive Phase 3 Results for Seasonal Influenza Vaccine Jun 12, 2025 7:25pm ET Moderna Receives U.S. FDA Approval for RSV Vaccine, mRESVIA, in Adults Aged 18–59 at Increased Risk for RSV Disease Jun 11, 2025 7:00am ET Moderna to Present at Upcoming Barclays Speaking the Science Call Series on June 16, 2025 May 31, 2025 12:16am ET Moderna Receives U.S. FDA Approval for COVID-19 Vaccine mNEXSPIKE May 28, 2025 6:00pm ET Moderna Announces Update on Investigational Pandemic Influenza Program May 27, 2025 7:00am ET Moderna to Present at Upcoming Conferences in June 2025 May 23, 2025 4:05pm ET Moderna Files FDA Application for the LP.8.1 Targeting COVID-19 Vaccine May 21, 2025 7:00am ET Moderna Provides Update on BLA Submission for Combination Vaccine Against Influenza and COVID-19 May 08, 2025 7:00am ET Moderna to Present at Upcoming Bernstein's 41st Annual Strategic Decisions Conference (SDC) on May 29, 2025 May 01, 2025 6:30am ET Moderna Reports First Quarter 2025 Financial Results and Provides Business Updates Apr 10, 2025 7:00am ET Moderna to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025 Apr 07, 2025 7:00am ET Moderna to Showcase Extensive Infectious Disease Research at ESCMID 2025 Mar 31, 2025 7:00am ET Moderna Receives Australian Therapeutic Goods Administration Approval for RSV Vaccine for Older Adults Feb 28, 2025 10:30am ET Moderna Receives Medicines and Healthcare Products Regulatory Agency Marketing Authorization in the UK for RSV Vaccine Feb 25, 2025 7:00am ET Moderna to Present at Upcoming Conferences in March 2025 Feb 14, 2025 6:28am ET Moderna Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Business Updates Jan 29, 2025 7:00am ET Moderna to Report Fourth Quarter and Full Year 2024 Financial Results on Friday, February 14, 2025 Jan 24, 2025 6:30am ET Moderna Awarded Tender for the Supply of Its mRNA COVID-19 Vaccine in the European Union Jan 17, 2025 4:28pm ET Moderna Announces Updates on Pandemic Influenza Program Jan 13, 2025 7:00am ET Moderna Provides Business and Pipeline Updates at 43rd Annual J.P. Morgan Healthcare Conference Nov 25, 2024 7:00am ET Moderna to Present at Upcoming Conferences in December 2024 Nov 03, 2024 12:27pm ET Shareholder Notice to Long-Term Shareholders of Moderna, Inc. (MRNA) Oct 08, 2024 4:00pm ET FINAL MRNA DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Moderna, Inc. Investors to Join the Class Action Lawsuit! Oct 08, 2024 3:13pm ET FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Moderna Oct 07, 2024 12:04pm ET Faruqi & Faruqi Reminds Moderna Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 8, 2024 - MRNA Oct 01, 2024 3:15pm ET MRNA DEADLINE NOTICE: ROSEN, A LONGSTANDING LAW FIRM, Encourages Moderna, Inc. Investors to Secure Counsel Before Important October 8 Deadline in Securities Class Action - MRNA Oct 01, 2024 1:44pm ET DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Moderna Sep 30, 2024 1:24pm ET SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Moderna Sep 28, 2024 1:01pm ET ROSEN, A TOP-RANKED LAW FIRM, Encourages Moderna, Inc. Investors to Secure Counsel Before Important October 8 Deadline in Securities Class Action - MRNA Sep 26, 2024 6:22pm ET DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Moderna Sep 26, 2024 5:47pm ET ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Moderna, Inc. Investors to Secure Counsel Before Important October 8 Deadline in Securities Class Action - MRNA Sep 25, 2024 5:46pm ET ROSEN, TOP RANKED NATIONAL INVESTOR ATTORNEYS, Encourages Moderna, Inc. Investors to Secure Counsel Before Important October 8 Deadline in Securities Class Action - MRNA Sep 24, 2024 10:06am ET DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Moderna Sep 22, 2024 8:48pm ET ROSEN, LEADING TRIAL ATTORNEYS, Encourages Moderna, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MRNA Sep 21, 2024 7:41pm ET ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Moderna, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MRNA Sep 20, 2024 12:34pm ET ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Moderna, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MRNA Sep 20, 2024 10:47am ET INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Moderna Sep 18, 2024 6:15pm ET ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Moderna, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MRNA Sep 18, 2024 5:24pm ET SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Moderna Sep 16, 2024 10:22am ET ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Moderna Sep 15, 2024 8:52pm ET ROSEN, TOP-RANKED INVESTOR COUNSEL, Encourages Moderna, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MRNA Sep 14, 2024 8:03am ET DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Moderna Sep 13, 2024 6:07pm ET ROSEN, A LEADING LAW FIRM, Encourages Moderna, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MRNA Sep 12, 2024 4:45pm ET ROSEN, LEADING INVESTOR COUNSEL, Encourages Moderna, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MRNA Sep 10, 2024 2:31pm ET ROSEN, A TOP-RANKED LAW FIRM, Encourages Moderna, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MRNA Sep 09, 2024 6:04pm ET DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Moderna Sep 07, 2024 4:00pm ET FINAL MRNA DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Moderna, Inc. Investors to Join the Class Action Lawsuit! Sep 07, 2024 2:15pm ET ROSEN, A LEADING LAW FIRM, Encourages Moderna, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MRNA Sep 07, 2024 8:33am ET INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Moderna Sep 06, 2024 2:14pm ET ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Moderna, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MRNA Sep 04, 2024 9:19pm ET ROSEN, LEADING TRIAL ATTORNEYS, Encourages Moderna, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MRNA Sep 03, 2024 9:18pm ET ROSEN, A LONGSTANDING LAW FIRM, Encourages Moderna, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MRNA Sep 02, 2024 8:24am ET ROSEN, NATIONAL TRIAL ATTORNEYS, Encourages Moderna, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MRNA Sep 02, 2024 7:44am ET DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Moderna Sep 01, 2024 7:38am ET SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Moderna Aug 31, 2024 3:18pm ET ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Moderna, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MRNA Aug 30, 2024 9:43am ET SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Moderna Aug 27, 2024 7:09pm ET ROSEN, A LEADING LAW FIRM, Encourages Moderna, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MRNA Aug 27, 2024 10:39am ET ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Moderna Aug 26, 2024 7:08pm ET ROSEN, LEADING INVESTOR COUNSEL, Encourages Moderna, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MRNA Aug 25, 2024 1:00pm ET ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Moderna, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MRNA Aug 24, 2024 7:38am ET DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Moderna Aug 22, 2024 6:01pm ET ROSEN, A GLOBALLY RECOGNIZED FIRM, Encourages Moderna, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MRNA Aug 22, 2024 5:34pm ET SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Moderna Aug 21, 2024 4:00pm ET MRNA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Moderna, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! Aug 21, 2024 1:17pm ET ROSEN, A LEADING LAW FIRM, Encourages Moderna, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MRNA Aug 20, 2024 10:43am ET SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Moderna Aug 19, 2024 4:18pm ET ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Moderna, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MRNA Aug 18, 2024 4:13pm ET ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Moderna, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MRNA Aug 18, 2024 8:33am ET DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Moderna Aug 17, 2024 4:12pm ET ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Moderna, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MRNA Aug 17, 2024 8:10am ET SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Moderna Aug 15, 2024 12:10pm ET MRNA Investors Have Opportunity to Lead Moderna, Inc. Securities Fraud Lawsuit with the Schall Law Firm Aug 15, 2024 9:42am ET ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Moderna Aug 14, 2024 12:38pm ET ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Moderna, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MRNA Aug 13, 2024 4:00pm ET MRNA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Moderna, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! Aug 13, 2024 10:57am ET DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Moderna Aug 12, 2024 3:10pm ET MRNA Investors Have Opportunity to Lead Moderna, Inc. Securities Fraud Lawsuit with the Schall Law Firm Aug 05, 2024 4:40pm ET SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Moderna, Inc. - MRNA Jul 28, 2024 10:16am ET SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Moderna, Inc. - MRNA Jul 16, 2024 3:16pm ET SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Moderna, Inc. - MRNA Jul 08, 2024 11:15am ET SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Moderna, Inc. - MRNA Jun 28, 2024 9:52am ET SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Moderna, Inc. - MRNA Jun 20, 2024 3:47pm ET SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Moderna, Inc. - MRNA

MRNA Financials

1-year income & revenue

  • Total revenue: $3.24B (1Y), $142.00M (Q2)

    Total Revenue decreased 52.69% since last year and increased 31.48% since last quarter.

  • Net income: -$3.56B (1Y), -$825.00M (Q2)

    Net Income increased 24.46% since last year and increased 15.04% since last quarter.

  • Earnings per share: -$9.27 (1Y), -$2.13 (Q2)

    EPS increased 24.85% since last year and increased 15.47% since last quarter.

Key terms

MRNA Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

MRNA Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range
  • How competitors are chosen

    MRNA's competitors are included in the Health Technology sector and Biotechnology group

  • Market cap: $10.44B

    A market capitalization between $10 billion and $200 billion places MRNA in the large capitalization category.

Key terms